Axa S.A. Has $225.59 Million Position in Zoetis Inc. (NYSE:ZTS)

Axa S.A. increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 10.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,301,285 shares of the company’s stock after purchasing an additional 126,070 shares during the period. Zoetis makes up 0.7% of Axa S.A.’s portfolio, making the stock its 26th biggest position. Axa S.A.’s holdings in Zoetis were worth $225,591,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. Aveo Capital Partners LLC acquired a new position in Zoetis during the 4th quarter worth approximately $225,000. Gryphon Financial Partners LLC boosted its holdings in Zoetis by 11.8% during the fourth quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock worth $601,000 after purchasing an additional 322 shares during the last quarter. Mitchell Sinkler & Starr PA grew its position in Zoetis by 30.2% in the fourth quarter. Mitchell Sinkler & Starr PA now owns 2,564 shares of the company’s stock valued at $506,000 after purchasing an additional 595 shares in the last quarter. United Services Automobile Association lifted its position in Zoetis by 8.1% during the 4th quarter. United Services Automobile Association now owns 13,682 shares of the company’s stock worth $2,700,000 after buying an additional 1,024 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its stake in shares of Zoetis by 14.6% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 47,662 shares of the company’s stock worth $9,407,000 after buying an additional 6,066 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ZTS has been the topic of a number of recent research reports. Stifel Nicolaus lifted their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Piper Sandler upped their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, BTIG Research upped their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Zoetis has an average rating of “Buy” and an average price target of $220.38.

Zoetis Trading Up 0.0 %

ZTS stock opened at $193.68 on Wednesday. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The stock has a market cap of $87.75 billion, a price-to-earnings ratio of 37.32, a price-to-earnings-growth ratio of 2.97 and a beta of 0.88. The company has a fifty day moving average price of $185.22 and a two-hundred day moving average price of $174.50. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The business had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. Zoetis’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.41 EPS. Equities analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.